Latest Conference Articles

AMG 160 showed preliminary evidence of efficacy with a manageable safety profile as treatment of patients with metastatic castration-resistant prostate cancer who have been heavily pretreated.

Patients with epithelial ovarian cancer treated with weekly dose-dense chemotherapy in the ICON8 clinical trial experienced similar progression-free survival and overall survival as patients treated with the standard-of-care.

Statistically significant and clinically meaningful improvements in both progression-free survival and overall survival were observed with the addition of tucatinib to trastuzumab and capecitabine as treatment of patients with HER2-positive metastatic breast cancer, irrespective of the presence of brain metastases.

Osimertinib plus bevacizumab did not lead to a prolonged progression-free survival compared with osimertinib alone as treatment of patients with advanced adenocarcinoma harboring EGFR T790M.

In the phase 2 single-arm innovaTV 204 trial, treatment with tisotumab vedotin led to an objective response rate (ORR) of 24% (95% CI, 15.9%-33.3%) in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab (Avastin). The encouraging result was announced during a presentation at the 2020 European Society of Medical Oncology (ESMO) Virtual Congress.

The combination of lenvatinib and pembrolizumab demonstrated responses in patients with previously treated advanced solid tumors in findings presented at the 2020 ESMO Virtual Congress from the phase 2 LEAP-005 trial.

A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.

Enfortumab vedotin monotherapy demonstrated significant long-term results in updated findings from the EV-201 trial presented at the 2020 ESMO Virtual Congress.

As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.

Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.

Updated findings from the randomized, open-label phase 3 PROfound trial indicate that olaparib induces a significantly longer duration of overall survival versus enzalutamide or abiraterone plus prednisone in metastatic castration-resistant prostate cancer tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and disease that has progressed during previous treatment with a next-generation hormonal agent.

Findings from the phase 1 CHRYSALIS study showed that patients with advanced EGFR-mutant non–small cell lung cancer who were treatment naïve or resistant to osimertinib therapy had high response rates when treated with the combination of amivantamab and lazertinib. Results also demonstrated a favorable safety profile for the regimen, according to results reported at the ESMO Virtual Congress 2020.

The combination of apatinib and gefitinib demonstrated the feasibility of dual VEGFR/EGFR inhibition in patients with advanced EGFR-mutant non–small cell lung cancer, according to progression-free survival results of the phase 3 ACTIVE trial that were reported at the ESMO Virtual Congress 2020.

Positive safety, pharmacokinetic, and pharmacodynamic data were reported for the first-in-human phase 1 dose-escalation trial of MGD019 during the European Society for Medical Oncology Virtual Congress 2020 as well as preliminary antitumor activity in select tumor types.

Patients with NTRK fusion–positive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib, according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.

Patients with completely resected stage IIIAN2 non–small cell lung cancer should not be recommended for post-operative radiotherapy, according to results from the phase 3 LungART trial that were presented during the ESMO Virtual Congress 2020, due to nonstatistically significant increase in disease-free survival versus those treated in the control group.

Findings from the phase 3 monarchE trial reported at the ESMO Virtual Congress 2020 showed that the risk of invasive disease with ​abemaciclib plus endocrine therapy was significantly reduced versus endocrine therapy alone in patients with high-risk early hormone receptor-positive, HER2-negative breast cancer.

Petros Grivas, MD, PhD, discusses the challenge with biomarker discovery currently in the treatment landscape of urothelial carcinoma.

The pathologic complete responses were significantly improved with neoadjuvant atezolizumab in combination with nab-paclitaxel plus doxorubicin and cyclophosphamide compared with placebo and chemotherapyin patients with stage 2 or stage 3 triple-negative breast cancer.

Patients with HR-positive, HER2-negative breast cancer experienced significant benefit when treated with neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide.

Patient-reported outcomes data showed the quality of life was not reduced with niraparib in patients with ovarian, primary peritoneal, or fallopian tube cancer compared with placebo.

A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Abemaciclib in combination with tamoxifen led to an improvement in overall survival compared with abemaciclib alone in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Notably, the benefit of the combination was observed across all subgroups in the study, according to findings from the final OS analysis of the nextMONARCH trial presented during the 2020 European Society of Medical Oncology Virtual Congress.

According to results from the phase 3 CROWN trial, the third-generation ALK tyrosine kinase inhibitor loralitinib achieved a significant improvement in progression-free survival as well as higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

In the phase 1 GARNET trial, durable antitumor activity was observed with dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer. The disease control rate was promising and the safety profile of the agent was tolerable, according to results presented during the 2020 European Society of Medical Oncology Virtual Congress.

Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.

The phase 3 COMBI-I clinical trial of spartalizumab plus dabrafenib and trametinib showed no improvement in investigator-assessed progression-free survival in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, missing the primary end point in part 3 of the study.

For patients with advanced gastrointestinal stromal tumors, there was continued clinically meaningful benefit with the novel broad-spectrum KIT and PDGFRα inhibitor ripretinib in the fourth line or later, according to updated data from the randomized phase 3 INVICTUS trial presented at the 2020 ESMO Virtual Congress.

The primary end point of investigator-assessed progression-free survival was missed in part 3 of the randomized, Phase 3 COMBI-i study of spartalizumab in combination with dabrafenib and trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, according to results presented at the 2020 ESMO Virtual Congress.

The use of encorafenib and binimetinib followed by immunotherapy demonstrated a higher progression-free survival, as well as an objective response rate and median PFS at 1 and 2 years that were consistent with those reported in pivotal studies, according to a presentation by Paolo Ascierto, MD, at the 2020 ESMO Virtual Congress.